EFFICACY AND SAFETY OF AFLIBERCEPT FOR THE TREATMENT OF IDIOPATHIC CHOROIDAL NEOVASCULARIZATION IN YOUNG PATIENTS: The INTUITION Study
| Autor: | Evelyne Decullier, Laure Huot, Stéphane Dumas, Thibaud Mathis, Ramin Tadayoni, Eric H Souied, Laurent Kodjikian, Joel Uzzan, Stéphanie Baillif, Solange Milazzo, Lorraine Bernard |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Indocyanine Green Male Vascular Endothelial Growth Factor A medicine.medical_specialty Visual acuity genetic structures Recombinant Fusion Proteins Visual Acuity Angiogenesis Inhibitors Young Adult Pro re nata Ophthalmology medicine Humans Treatment effect In patient Prospective Studies Fluorescein Angiography Adverse effect Coloring Agents Aflibercept business.industry General Medicine Middle Aged Choroidal Neovascularization Regimen Choroidal neovascularization Receptors Vascular Endothelial Growth Factor Treatment Outcome Intravitreal Injections Female medicine.symptom business medicine.drug Follow-Up Studies |
| Zdroj: | Retina (Philadelphia, Pa.). 42(2) |
| ISSN: | 1539-2864 |
| Popis: | To evaluate the mean change in visual acuity at 52 weeks in patients with idiopathic choroidal neovascularization treated with aflibercept.We conducted a prospective noncomparative open-label Phase-II trial. The dosage regimen evaluated in this study was structured into two periods: (1) from inclusion to 20 weeks: a treat-and-extend period composed of three mandatory intravitreal injections, and complementary intravitreal injections performed if needed; (2) from 21 weeks to 52 weeks: a pro re nata period composed of intravitreal injections performed only if needed.A total of 19 patients were included, and 16 completed the 52-week study. At baseline, the mean best corrected visual acuity was 66.56 (±20.72) letters (≈20/50 Snellen equivalent), and the mean central retinal thickness was 376.74 µm (±93.77). At 52 weeks, the mean change in the best-corrected visual acuity was +19.50 (±19.36) letters [95% confidence interval = +9.18 to +29.82]. None of the patients included lost ≥15 letters at 24 weeks or 52 weeks. The mean change in central retinal thickness was -96.78 µm (±104.29) at 24 weeks and -86.22 µm (±112.27) at 52 weeks. The mean number of intravitreal injections was 5.4 (±3.0) at 52-weeks. No ocular serious adverse events related to the treatment were reported.The present analysis shows clinically significant functional and anatomical treatment effect of aflibercept in case of idiopathic choroidal neovascularization. The treat-and-extend regimen proposed after the first injection seems adequate to treat most neovessels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|